A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy
Treatment and Treatment Duration Neoadjuvant chemotherapy will begin on Day 1 of Cycle 1 and will be administered every 2 weeks for a total of 4 cycles.
After surgery, XELOX, which is currently used as standard adjuvant chemotherapy, will be administered for 6-8 cycles at the physician's discretion.
Study Duration The study duration is expected to be approximately 3 years from the date of IRB approval.
(The study duration may be subject to change depending on the enrollment rate.) Number of Subjects The target enrollment for this study is 20 subjects. Investigational Products, Dose, and Rou